2024-03-13T22:36:40.580Z

ANZadapt

ANZadapt
Prostate cancer

A Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)

A Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)

Trial overview

Topic

Prostate cancer

Trial registration

Number: NCT05393791

Study details

This study aims to find out if this pause/restart strategy is better than taking hormone tablets every day continuously. The study will include 168 people with metastatic castrate resistant prostate cancer in the Netherlands and Australia.

Further information

Click here for further information

Location

GenesisCare North Shore – PI: Dr Laurence Krieger

GenesisCare North Shore – PI: Dr Laurence Krieger :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.